My research interests are directed toward improving outcomes for patients with lymphoid malignancies through the development of novel treatments and other targeted therapies. A major focus has been the evaluation of new monoclonal antibody therapeutics, and our group has studied most of the anti-B cell agents in the clinic.  Demonstration of the safety and activity of these agents has resulted in their subsequent evaluation in phase II and III trials.  I have led National Cancer Institute cooperative group studies with the Cancer and Leukemia Group B (CALGB) evaluating “combination antibody” or “combination biologic” approaches for B cell malignancies and other lymphomas. This class of agents has improved survival for lymphoma patients over the last decade, and our work has led to larger ongoing international studies that aim to further enhance patient outcomes in the future. Additionally, we have assessed the role of prognostic, imaging and survivorship issues in the management of lymphoma patients, and provided new insights into prognosis and outcomes of patients with specific lymphoid malignancies including mantle cell lymphoma. Our current collaborative work also includes translational studies which are assessing novel therapeutics directed against epigenetic, signaling, immune, and vascular pathways in the treatment of lymphoid cancers. We continue to pilot novel treatment approaches in limited scale translational studies, which can then lead to larger studies providing a broader evaluation in greater numbers of patients.  Additionally I have served as the leader of the Lymphoma Committee for the Alliance for Clinical Trials for Oncology, a cooperative group of the National Cancer Institute's National Clinical Trials Network, which have helped to define and conduct the national clinical trials portfolio in lymphoma.